Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth

This study demonstrates that the MEK inhibitor mirdametinib exhibits single-agent activity against atypical teratoid rhabdoid tumor (ATRT) and, when combined with the CDK4/6 inhibitor abemaciclib, significantly suppresses tumor proliferation and extends survival in orthotopic xenograft models.

The Gist

The Problem: A Tough Brain Tumor in Kids

Imagine a child's brain as a bustling, well-organized city. In Atypical Teratoid Rhabdoid Tumor (ATRT), a very aggressive type of brain cancer found in infants and young children, a specific "construction manager" (a protein called SMARCB1) goes missing.

Without this manager, the city's construction crews (the cells) stop following the rules. Instead of building mature, specialized buildings (healthy brain tissue), they stay stuck in a chaotic, baby-like state where they just keep multiplying uncontrollably. This creates a tumor that grows fast and is very hard to treat. Currently, even with aggressive surgery and radiation, less than 40% of children survive. We need new tools to stop this chaos.

The Discovery: A "Speed Limit" for the Tumor

The researchers discovered that these runaway cells have a "gas pedal" stuck to the floor. This gas pedal is a signaling pathway called MAPK. It tells the cells to grow, divide, and invade.

They found a new drug called Mirdametinib. Think of this drug as a high-tech brake pedal.

• The Old Brakes: Previous drugs tried to press the brake, but they were like old, rusty brakes that couldn't reach the tumor inside the brain (they couldn't cross the "blood-brain barrier," which acts like a strict security checkpoint).
• The New Brake: Mirdametinib is a newer, smarter brake. It is small and slippery enough to slip past the security checkpoint, enter the brain, and firmly press the gas pedal down, slowing the tumor cells way down.

The Experiment: Testing the Brake

The team tested this "brake" on different types of ATRT tumors (like testing a car on different terrains).

1. In the Lab: When they added Mirdametinib to tumor cells in a dish, the cells stopped multiplying. It was like hitting the pause button on a video. The cells also started to self-destruct (a process called apoptosis), which is the body's way of cleaning up broken machinery.
2. In Mice: They grew these tumors inside mice brains. When they gave the mice Mirdametinib, the tumors grew much slower, and the mice lived significantly longer. Crucially, the drug didn't make the mice sick or lose weight, meaning it was safe to use.

The Power-Up: Adding a Second Tool

While the brake worked well on its own, the researchers wondered: What if we add a second tool to make it even stronger?

They paired Mirdametinib with a second drug called Abemaciclib.

• The Analogy: If Mirdametinib is the brake pedal, Abemaciclib is like cutting the fuel line.
  • Mirdametinib stops the signal to "go."
  • Abemaciclib blocks the engine from shifting gears into "drive" (specifically, it stops the cells from entering the phase where they copy their DNA to divide).

When they used both drugs together, the effect was like slamming on the brakes and cutting the fuel at the same time. The tumor cells didn't just slow down; they were completely stopped. In the mice, this combination therapy extended their lives even more than the single drug did.

The Big Picture

This study is a beacon of hope for families facing ATRT.

• Mirdametinib is already approved for other conditions and is safe for kids.
• Abemaciclib is also an approved drug for breast cancer.
• The Combination: By using these two existing drugs together, the researchers found a way to attack the tumor from two different angles without causing severe side effects.

In summary: The researchers found a way to sneak a "brake" (Mirdametinib) into the brain to stop a runaway tumor. Then, they added a "fuel cutter" (Abemaciclib) to make sure the tumor stays stopped. This combination slowed the cancer down and helped the mice live longer, suggesting this could be a powerful new treatment strategy for children with this difficult disease.

Technical Summary

1. Problem Statement

Atypical Teratoid Rhabdoid Tumor (ATRT) is the most common malignant brain tumor in infants, characterized by the loss of the SMARCB1 gene (a component of the mSWI/SNF complex). This loss leads to epigenetic dysregulation, preventing cell differentiation and maintaining a stem-cell state.

• Clinical Challenge: Despite aggressive therapy (surgery, high-dose chemotherapy, radiation, and stem cell transplant), overall survival remains below 40%.
• Molecular Driver: Previous research by the authors identified that LIN28A/B overexpression suppresses let-7 microRNAs, leading to the upregulation of KRAS and hyperactivation of the Mitogen-Activated Protein Kinase (MAPK) pathway in ATRT.
• Therapeutic Gap: While MEK inhibitors (e.g., selumetinib, binimetinib) showed efficacy in vitro and in heterotopic models, their poor blood-brain barrier (BBB) penetration limited their utility in treating intracranial ATRT. There is an urgent need for brain-penetrant agents that target the MAPK pathway.

2. Methodology

The study utilized a multi-modal approach combining in vitro cell culture, in vivo orthotopic xenograft models, and molecular profiling.

• Cell Models: A panel of ATRT cell lines representing the three major molecular subgroups (MYC, TYR, and SHH) was used: CHLA-04, CHLA-05, CHLA-06, BT37, BT12, BT16, MAF737, and CHLA266.
• Pharmacological Agents:
  • Mirdametinib: A next-generation, brain-penetrant MEK inhibitor (FDA-approved for plexiform neurofibromas).
  • Abemaciclib: A brain-penetrant CDK4/6 inhibitor.
• In Vitro Assays:
  • Western Blotting: To assess pathway inhibition (p-ERK, p-Rb, Cleaved PARP).
  • Proliferation: Measured via BrdU incorporation (immunofluorescence and flow cytometry) and cell growth curves (Muse Cell Analyzer).
  • Apoptosis: Quantified via Annexin V flow cytometry and Cleaved Caspase-3 (CC3) immunofluorescence.
  • IC50 Determination: Dose-response curves to establish drug sensitivity.
• In Vivo Models:
  • Orthotopic Xenografts: Luciferase-expressing ATRT cells (MAF737-TYR and CHLA06-MYC) were implanted into the brains of mice.
  • Treatment Regimens:
    • Mirdametinib: 15 mg/kg, oral gavage, 5 days/week (monotherapy) or 3 days/week (combination).
    • Abemaciclib: 50 mg/kg, oral gavage, 5 days/week.
  • Monitoring: Tumor growth tracked via bioluminescence imaging (IVIS); survival monitored; toxicity assessed via weekly weight measurements.
  • Endpoint Analysis: Tumors were harvested for Western blot analysis of phospho-ERK to confirm on-target activity.

3. Key Contributions

1. Validation of Brain-Penetrant MEK Inhibition: Demonstrated that mirdametinib effectively crosses the blood-brain barrier in mouse models, suppresses the MAPK pathway (p-ERK), and induces apoptosis in ATRT.
2. Synergistic Combination Strategy: Established a novel therapeutic combination of Mirdametinib (MEK inhibitor) and Abemaciclib (CDK4/6 inhibitor). The study hypothesized and proved that targeting the MAPK pathway (upstream) and the cell cycle (downstream via Rb) creates a synergistic effect without overlapping toxicity.
3. Subgroup Agnosticism: Showed efficacy across all major molecular subgroups of ATRT (MYC, TYR, and SHH), suggesting a broad applicability of this strategy.
4. Clinical Translation Potential: Provided preclinical data supporting the repurposing of mirdametinib (already FDA-approved for NF1) and abemaciclib (FDA-approved for breast cancer) for pediatric ATRT.

4. Key Results

A. In Vitro Efficacy

• MAPK Suppression: Mirdametinib inhibited p-ERK at nanomolar concentrations across all tested cell lines.
• Potency: IC50 values ranged from 6.4 nM to 2557 nM, with most lines showing sensitivity in the low nanomolar range (e.g., CHLA06: 6.4 nM; BT16: 29.4 nM).
• Proliferation & Apoptosis: Treatment significantly reduced BrdU incorporation (e.g., CHLA06 dropped from 67% to 18% positivity) and induced apoptosis (increased Cleaved PARP and CC3).
• Combination Effect: The combination of mirdametinib and abemaciclib further reduced phospho-Rb (indicating G1/S arrest) and BrdU incorporation compared to monotherapy across all subgroups.

B. In Vivo Efficacy (Orthotopic Xenografts)

• Monotherapy (Mirdametinib):
  • MAF737 (TYR): Delayed tumor growth and significantly extended survival (Median survival: Control 38 days vs. Mirdametinib >75 days; p=0.0018).
  • CHLA06 (MYC): Extended survival from 17 days (control) to 24 days (p=0.037).
  • Toxicity: No significant weight loss was observed, indicating good tolerability.
• Combination Therapy (Mirdametinib + Abemaciclib):
  • Tumor Growth: Significantly suppressed tumor progression compared to control and monotherapy in CHLA06, BT16, MAF737, BT37, and CHLA05 models.
  • Survival: In the aggressive CHLA06 model, median survival increased from 17 days (control) to 33 days (combination therapy).
  • Mechanism Confirmation: Western blots of harvested tumors confirmed reduced p-ERK levels, verifying on-target pharmacodynamics.

5. Significance and Conclusion

This study identifies the MAPK pathway as a critical vulnerability in ATRT and validates mirdametinib as a potent, brain-penetrant therapeutic agent capable of single-agent activity.

The most significant finding is the synergistic efficacy of combining mirdametinib with abemaciclib. This combination targets both the upstream driver (MAPK) and the downstream cell cycle machinery (CDK4/6-Rb axis), resulting in:

1. Superior suppression of tumor proliferation.
2. Significant extension of survival in aggressive orthotopic models (nearly doubling survival in the MYC subtype).
3. Minimal toxicity, allowing for sustained dosing.

Clinical Implication: These findings strongly support the initiation of clinical trials for ATRT patients using the mirdametinib/abemaciclib combination. Given that both drugs have established safety profiles in pediatric populations (mirdametinib for NF1, abemaciclib for high-grade glioma trials), this strategy offers a rapid pathway to improve outcomes for children with this otherwise fatal disease.